Abivax SA Files Prospectus with SEC for $747.5 Million Public Offering, Aiming to Finance Operations into 2027

Reuters
07-29
<a href="https://laohu8.com/S/AAVXF">Abivax SA</a> Files Prospectus with SEC for $747.5 Million Public Offering, Aiming to Finance Operations into 2027

Abivax SA, a clinical-stage biotechnology company, announced the closing of its underwritten public offering of 11,679,400 American Depositary Shares (ADSs) in the United States, raising approximately $747.5 million in gross proceeds. The offering, which includes the full exercise of the underwriters' option to purchase additional ADSs, aims to finance the company's operations into the fourth quarter of 2027. This financial strategy supports Abivax's ambition to achieve a 12-month cash runway following its planned NDA submission for Ulcerative Colitis. The company's Ordinary Shares are listed on Euronext Paris under the symbol "ABVX," and its ADSs are on the Nasdaq Global Market. The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital, BTIG, and Van Lanschot Kempen as co-managers. An automatic shelf registration statement on Form F-3, including a prospectus, was filed with the SEC and is available on their website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001120142-en) on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10